The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

This new treatment could help bring relief for millions of Americans struggling with depression. The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...